Home
Explore
Substances
Ailments
Problem Substances
Therapeutic Actions
Problematic Actions
Pharmacological Actions
Adverse Pharmacological Actions
Keywords
Health Guides
Recent Comments
Authors
GMTV
Tools
SS - Query Diseases
SS - Query Pharmacological Actions
SS - Query Substances
Articles
Most Popular
Most Recent
Eatmology
Store
Membership Options
Books
Downloadable Documents
Events
Event Videos
GMI Tokens
Donate
My Account
My Comments
My Cart
My Newsletters
FAQ
Contact
Search this site:
Search
Download Now
Your Token Count
0
Sign in to Purchase/Download Documents
Sign in
/
Register
User login
Username or e-mail:
*
Password:
*
Log in
Create new account
Request new password
Social Networking
Support Free Media
Become A Sponsor
View Our Sponsors
Advertise/Collaborate
Become a Member
Become an Affiliate
Link To Us
About Us
Rosiglitazone (trade name Avandia)
23
Tweet
Related Topic
-
Avandia
User Options
Hover over an icon for more information
Additional Topics Details for this Page
Article Count
- 15
Cumulative Knowledge
- 106
Advanced Database Options
Limit Articles Displayed by the Following Study Types
Animal Study
Commentary
Human Study
Human: Case Report
Meta Analysis
Submit
Available Sorting Options
Limited to Members Only
By default, all articles on GreenMedInfo.com are sorted based on the content type which best reflects the data which most users are searching for. For instance, people viewing substances are generally most interested in viewing diseases that these substances have shown to have positive influences. This section is for allowing more advanced sorting methods. Currently, these advanced sorting methods are available for members only. If you are already a member, you can sign in by
clicking here
. If you do not currently have a user account, and would like to create one/become a member,
click here
to begin the singup process.
Currently Available Sorting Options
Article Published Date
- Sort all displayed articles by their published date
Quick Summary Fieldsets
- Sort alphabetically, rather than by Cumulative Knowledge
Cumulative Knowledge
- Default sorting method. Allows you to sort descendingly
What is Cumulative Knowledge?
Cumulative Knowledge
is determined by ascribing a numerical value to the various study types weighted in descending order as follows: (1) Meta-Analysis; (2) Human Study; (3) Human: Case Study; (4) Animal: Transgenic; (5) Animal; (6) In Vitro; (7) Review; and (8) Commentary.
Click here for a more thorough explanation.
Quick Summary: Current access displays 2 out of 23 associated Diseases
Name
Cumulative Knowledge
Article Count
Focus Articles
Diabetes Mellitus: Type 2
74
7
Log in
|
Sign up
Myocardial Infarction
70
5
Log in
|
Sign up
Quick Summary: Current access displays 2 out of 3 associated Adverse Pharmacological Actions
Name
Cumulative Knowledge
Article Count
Focus Articles
Cardiotoxic
62
5
Log in
|
Sign up
Hepatotoxic
4
2
Log in
|
Sign up
Currently Viewing Free Sample of Member Only Features
Although all 19,000+ articles on GreenMedInfo.com are made entirely free to view as an educational service to the public, we provide a powerful set of enhanced data comprehension and retrieval tools for subscribing members. Above you are viewing a free preview, limited to 2 rows, of the membership feature called "
Cumulative Knowledge
" (
learn more
).
The
Focus Article Feature
is not enabled.
Upgrading to the
Member
role gives you access to unlimited rows of Cumulative Knowledge data.
To Participate
Click here
to login
Click here
to create an account
View the Evidence: Problem Substances
Among patients with impaired glucose tolerance or type 2 diabetes, rosiglitazone use for at least 12 months is associated with a significantly increased risk of myocardial infarction and heart failure.
Click here to read the entire abstract
Pubmed Data
: JAMA. 2007 Sep 12;298(10):1189-95. PMID:
17848653
Article Published Date
: Sep 12, 2007
Study Type
: Meta Analysis
Additional Links
Diseases
:
Cardiovascular Diseases : CK(5138) : AC(641)
,
Diabetes Mellitus: Type 2 : CK(3429) : AC(341)
,
Heart Failure : CK(711) : AC(97)
,
Myocardial Infarction : CK(2632) : AC(117)
Problem Substances
:
Rosiglitazone (trade name Avandia) : CK(106) : AC(15)
Adverse Pharmacological Actions
:
Cardiotoxic : CK(638) : AC(79)
Rosiglitazone was associated with a significant increase in the risk of myocardial infarction and with an increase in the risk of death from cardiovascular causes.
Click here to read the entire abstract
Pubmed Data
: N Engl J Med. 2007 Jun 14;356(24):2457-71. Epub 2007 May 21. PMID:
17517853
Article Published Date
: Jun 14, 2007
Study Type
: Meta Analysis
Additional Links
Diseases
:
Cardiac Mortality : CK(703) : AC(67)
,
Cardiovascular Diseases : CK(5138) : AC(641)
,
Diabetes: Cardiovascular Illness : CK(666) : AC(104)
,
Diabetes Mellitus: Type 2 : CK(3429) : AC(341)
,
Myocardial Infarction : CK(2632) : AC(117)
Problem Substances
:
Rosiglitazone (trade name Avandia) : CK(106) : AC(15)
Adverse Pharmacological Actions
:
Cardiotoxic : CK(638) : AC(79)
Rosiglitazone and pioglitazone increase fracture risk in women and men with type 2 diabetes.
Click here to read the entire abstract
Pubmed Data
: Diabetes Obes Metab. 2010 Aug;12(8):716-21. PMID:
20590749
Article Published Date
: Aug 01, 2010
Study Type
: Human Study
Additional Links
Diseases
:
Bone Fractures : CK(1610) : AC(69)
,
Diabetes Mellitus: Type 2 : CK(3429) : AC(341)
,
Hip Fracture : CK(1724) : AC(21)
,
Osteoporosis : CK(1171) : AC(205)
Problem Substances
:
Rosiglitazone (trade name Avandia) : CK(106) : AC(15)
Rosiglitazone use is associated with an increased risk of acute myocardial infarction in the elderly.
Click here to read the entire abstract
Pubmed Data
: Diab Vasc Dis Res. 2009 Apr;6(2):87-93. PMID:
20368198
Article Published Date
: Apr 01, 2009
Study Type
: Human Study
Additional Links
Diseases
:
Elderly: Age Specific Diseases : CK(442) : AC(37)
,
Heart Failure : CK(711) : AC(97)
,
Myocardial Infarction : CK(2632) : AC(117)
Problem Substances
:
Rosiglitazone (trade name Avandia) : CK(106) : AC(15)
Adverse Pharmacological Actions
:
Cardiotoxic : CK(638) : AC(79)
Rosiglitazone use is associated with an increased risk of stroke, heart failure, and all-cause mortality.
Click here to read the entire abstract
Pubmed Data
: JAMA. 2010 Jul 28;304(4):411-8. Epub 2010 Jun 28. PMID:
20584880
Article Published Date
: Jul 28, 2010
Study Type
: Human Study
Additional Links
Diseases
:
Cardiac Mortality : CK(703) : AC(67)
,
Diabetes Mellitus: Type 2 : CK(3429) : AC(341)
,
Heart Failure : CK(711) : AC(97)
,
Mortality: All-Cause : CK(644) : AC(55)
,
Myocardial Infarction : CK(2632) : AC(117)
,
Stroke : CK(540) : AC(47)
Problem Substances
:
Rosiglitazone (trade name Avandia) : CK(106) : AC(15)
Adverse Pharmacological Actions
:
Cardiotoxic : CK(638) : AC(79)
The use of rosiglitazone (Avandia) in type 2 diabetic patients is associated with an increased risk of heart failure and of some fractures, mainly in women.
Click here to read the entire abstract
Pubmed Data
: Lancet. 2009 Jun 20;373(9681):2125-35. Epub 2009 Jun 6. PMID:
19501900
Article Published Date
: Jun 20, 2009
Study Type
: Human Study
Additional Links
Diseases
:
Diabetes Mellitus: Type 2 : CK(3429) : AC(341)
,
Heart Failure : CK(711) : AC(97)
,
Myocardial Infarction : CK(2632) : AC(117)
,
Osteoporosis : CK(1171) : AC(205)
Additional Keywords
:
Drug: Metformin : CK(195) : AC(23)
Problem Substances
:
Rosiglitazone (trade name Avandia) : CK(106) : AC(15)
The use of rosiglitazone (Avandia) in type 2 diabetic patients is associated with increased risk of heart failure.
Click here to read the entire abstract
Pubmed Data
: Eur Heart J. 2010 Jan 29. Epub 2010 Jan 29. PMID:
20118174
Article Published Date
: Jan 29, 2010
Study Type
: Human Study
Additional Links
Diseases
:
Cardiac Mortality : CK(703) : AC(67)
,
Diabetes: Cardiovascular Illness : CK(666) : AC(104)
,
Heart Failure : CK(711) : AC(97)
Problem Substances
:
Rosiglitazone (trade name Avandia) : CK(106) : AC(15)
Paradoxical severe decrease in high-density lipoprotein cholesterol due to rosiglitazone-fenofibrate interaction has been reported.
Click here to read the entire abstract
Pubmed Data
: Endocr Pract. 2010 May-Jun;16(3):382-8. PMID:
20061291
Article Published Date
: May 01, 2010
Study Type
: Human: Case Report
Additional Links
Diseases
:
Cholesterol: LDL/HDL ratio : CK(432) : AC(58)
,
Diabetes Mellitus: Type 2 : CK(3429) : AC(341)
,
HDL: Low : CK(255) : AC(45)
Problem Substances
:
Fenofibrates : CK(133) : AC(19)
,
Rosiglitazone (trade name Avandia) : CK(106) : AC(15)
Rosiglitazon is able to induce primary DNA damage in rats, with greater damage being detected in liver cells than lymphocytes.
Click here to read the entire abstract
Pubmed Data
: Environ Mol Mutagen. 2006 Dec;47(9):718-24. PMID:
17078099
Article Published Date
: Dec 01, 2006
Study Type
: Animal Study
Additional Links
Diseases
:
Chemically-Induced Liver Damage : CK(475) : AC(175)
,
DNA damage : CK(711) : AC(293)
,
Drug Toxicity : CK(4) : AC(2)
Problem Substances
:
Rosiglitazone (trade name Avandia) : CK(106) : AC(15)
Adverse Pharmacological Actions
:
Genotoxic : CK(146) : AC(61)
,
Hepatotoxic : CK(283) : AC(80)
Rosiglitazone causes bone loss in mice by suppressing osteoblast (bone-building cells) differentiation and bone formation.
Click here to read the entire abstract
Pubmed Data
: Endocrinology. 2005 Mar;146(3):1226-35. Epub 2004 Dec 9. PMID:
15591153
Article Published Date
: Mar 01, 2005
Study Type
: Animal Study
Additional Links
Diseases
:
Aging : CK(1351) : AC(369)
,
Osteopenia : CK(207) : AC(41)
,
Osteoporosis : CK(1171) : AC(205)
Additional Keywords
:
Accelerated Aging : CK(4) : AC(2)
Problem Substances
:
Rosiglitazone (trade name Avandia) : CK(106) : AC(15)
Rosiglitazone causes cardiac hypertrophy.
Click here to read the entire abstract
Pubmed Data
: J Mol Cell Cardiol. 2009 Jul;47(1):85-95. Epub 2009 May 3. PMID:
19397913
Article Published Date
: Jul 01, 2009
Study Type
: Animal Study
Additional Links
Diseases
:
Cardiac Hypertrophy : CK(54) : AC(22)
,
Cardiomegaly : CK(13) : AC(7)
Problem Substances
:
Rosiglitazone (trade name Avandia) : CK(106) : AC(15)
Adverse Pharmacological Actions
:
Cardiotoxic : CK(638) : AC(79)
Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone.
Click here to read the entire abstract
Pubmed Data
: Endocrinology. 2007 Jun;148(6):2669-80. Epub 2007 Mar 1. PMID:
17332064
Article Published Date
: Jun 01, 2007
Study Type
: Animal Study
Additional Links
Diseases
:
Aging : CK(1351) : AC(369)
,
Osteopenia : CK(207) : AC(41)
,
Osteoporosis : CK(1171) : AC(205)
Additional Keywords
:
Accelerated Aging : CK(4) : AC(2)
Problem Substances
:
Rosiglitazone (trade name Avandia) : CK(106) : AC(15)
Rosiglitazone may increase the risk of bone fracture by increasing osteoclast (bone-dissolving cells) generation.
Click here to read the entire abstract
Pubmed Data
: Cell Metab. 2010 Jun 9;11(6):503-16. PMID:
20519122
Article Published Date
: Jun 09, 2010
Study Type
: Animal Study
Additional Links
Diseases
:
Osteoporosis : CK(1171) : AC(205)
,
Osteoporosis: Over-active Osteoclasts : CK(5) : AC(3)
Problem Substances
:
Rosiglitazone (trade name Avandia) : CK(106) : AC(15)
Thiazolidinediones appear to have hepatotoxic properties.
Click here to read the entire abstract
Pubmed Data
: Life Sci. 2007 Jan 30;80(8):732-40. Epub 2006 Nov 10. PMID:
17126857
Article Published Date
: Jan 30, 2007
Study Type
: Animal Study
Additional Links
Diseases
:
Chemically-Induced Liver Damage : CK(475) : AC(175)
,
Drug Toxicity : CK(4) : AC(2)
Problem Substances
:
Rosiglitazone (trade name Avandia) : CK(106) : AC(15)
,
Thiazolidinediones : CK(2) : AC(1)
Adverse Pharmacological Actions
:
Hepatotoxic : CK(283) : AC(80)
Diabetic edematous maculopathy associated with rosiglitazone treatment has been reported.
Click here to read the entire abstract
Pubmed Data
: Bull Soc Belge Ophtalmol. 2009(313):39-44. PMID:
20108571
Article Published Date
: Jan 01, 2009
Study Type
: Commentary
Additional Links
Diseases
:
Diabetes: Eye Disease : CK(4) : AC(3)
,
Diabetes Mellitus: Type 2 : CK(3429) : AC(341)
Problem Substances
:
Rosiglitazone (trade name Avandia) : CK(106) : AC(15)
Print Options
Some features are currently member only features. If you are already a member, please
login
. Otherwise,
click here
to become a member.
Printer-friendly version
Send to friend
PDF version
Privacy Policy
Return Policy
About Us
Contact Us
Sitemap